Myeloid-targeted RNA nanotherapeutics rewire cholesterol metabolism to unleash anti-tumor immunity in glioblastoma
Huo, J.; Lin, H.; Li, Y.; Tripathi, S.; Chojak, R.; Silvers, C.; Peng, Y.; Boland, L.; Zhang, J.; McCortney, K.; Perera, R. M.; Najem, H.; Billingham, L. K.; Chia, T.-Y.; Chen, X.; Wang, H.; Sun, J.; Siringan, M. J.; Jing, L.; Musabji, A.; Congivaram, H.; Wang, S.; Lopez-Rosas, A.; Kumthekar, P.; Jamshidi, P.; Ahmed, A. U.; Lee-Chang, C.; Chandler, J. P.; Youngblood, M. W.; Sonabend, A.; Tate, M. C.; Shah, H.; Thorp, E. B.; Lesniak, M. S.; Heimberger, A. B.; Miska, J.; Zhang, P.
Show abstract
Tumor-associated myeloid cells (TAMCs) dominate the glioblastoma (GBM) microenvironment and suppress anti-tumor immunity. Here, we identify cholesterol efflux via ABCA1 as a targetable metabolic checkpoint controlling TAMC immunosuppression in GBM. Reprogramming TAMC cholesterol metabolism using TAMC-targeting lipid nanoparticle encapsulating ABCA1 siRNA (ABCA1 LNP) converts TAMCs into potent antigen-presenting cells with enhanced pro-inflammatory activity and antigen-presenting capacity, thereby inducing T cell activation, expansion, and tumor infiltration. Mechanistically, ABCA1 blockade induces cholesterol accumulation in TAMC membranes, promoting lipid raft formation and enhancing MHC-I-mediated antigen presentation. In multiple preclinical GBM models, ABCA1 LNP treatment dramatically induces T cell priming, extends animal survival, and overcomes GBM resistance to radiotherapy and immune checkpoint therapy. This efficacy was well-maintained in stem-like and recurrent GBM models, GBM patient specimens, and a renal cell carcinoma model. Altogether, our work identifies cholesterol efflux as a targetable metabolic vulnerability in TAMCs to overcome therapy resistance in myeloid-rich, immunologically "cold" tumors.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Agonistic CD40 antibody therapy induces tertiary lymphoid structures but impairs the response to immune checkpoint blockade in glioma 95%
- Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma 94%
- Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations 94%
Similar papers in this journal
- Single-nucleus and spatial landscape of the sub-ventricular zone in human glioblastoma 94%
- The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability 94%
- NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas 94%
Similar papers in this journal
- Glioma-associated tertiary lymphoid structures are sites of lymphocyte clonal expansion and plasma cell formation 94%
- Spatial patterning and immunosuppression of glioblastoma immune contexture in hypoxic niches 93%
- Germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques 93%
Similar papers in this journal
- Astrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation 94%
- Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response 93%
- Loss of the intracellular enzyme QPCTL limits chemokine function and reshapes myeloid infiltration to augment tumor immunity 92%
Similar papers in this journal
- A new universal chimeric-antigen receptor (CAR)- fragment antibody binder (FAB) split system for cancer immunotherapy 93%
- Deciphering sources of PET signals in the tumor microenvironment of glioblastoma at cellular resolution 93%
- Cytostatic hypothermia and its impact on glioblastoma and survival 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.